INNOGEN-B (02591) Rises Over 5% Again, Set to Join Hang Seng Composite Index Next Monday; Analysts Say It Meets Southbound Trading Eligibility

Stock News12-05

INNOGEN-B (02591) surged over 5% again, marking a three-day winning streak. At press time, the stock rose 5.03% to HK$43.42, with a turnover of HK$7.64 million.

The Hang Seng Indexes Company previously announced quarterly review results, confirming INNOGEN-B's inclusion in the Hang Seng Composite Index, effective December 8, 2025. Analysts at CICC predict the company meets eligibility criteria for Southbound Stock Connect.

Public filings show INNOGEN-B is a biopharmaceutical firm specializing in metabolic diseases, with multiple self-developed innovative drug pipelines targeting diabetes, obesity, and non-alcoholic steatohepatitis. The company holds global intellectual property rights and maintains worldwide R&D and market operations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1131099379?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-05 10:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131099379","market":"hk","top_or_hot":-1,"title":"INNOGEN-B (02591) Rises Over 5% Again, Set to Join Hang Seng Composite Index Next Monday; Analysts Say It Meets Southbound Trading Eligibility","media":"Stock News","content":"<p>INNOGEN-B (02591) surged over 5% again, marking a three-day winning streak. At press time, the stock rose 5.03% to HK$43.42, with a turnover of HK$7.64 million.</p>\n<p>The Hang Seng Indexes Company previously announced quarterly review results, confirming INNOGEN-B's inclusion in the Hang Seng Composite Index, effective December 8, 2025. Analysts at CICC predict the company meets eligibility criteria for Southbound Stock Connect.</p>\n<p>Public filings show INNOGEN-B is a biopharmaceutical firm specializing in metabolic diseases, with multiple self-developed innovative drug pipelines targeting diabetes, obesity, and non-alcoholic steatohepatitis. The company holds global intellectual property rights and maintains worldwide R&D and market operations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INNOGEN-B (02591) Rises Over 5% Again, Set to Join Hang Seng Composite Index Next Monday; Analysts Say It Meets Southbound Trading Eligibility</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINNOGEN-B (02591) Rises Over 5% Again, Set to Join Hang Seng Composite Index Next Monday; Analysts Say It Meets Southbound Trading Eligibility\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-05 10:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INNOGEN-B (02591) surged over 5% again, marking a three-day winning streak. At press time, the stock rose 5.03% to HK$43.42, with a turnover of HK$7.64 million.</p>\n<p>The Hang Seng Indexes Company previously announced quarterly review results, confirming INNOGEN-B's inclusion in the Hang Seng Composite Index, effective December 8, 2025. Analysts at CICC predict the company meets eligibility criteria for Southbound Stock Connect.</p>\n<p>Public filings show INNOGEN-B is a biopharmaceutical firm specializing in metabolic diseases, with multiple self-developed innovative drug pipelines targeting diabetes, obesity, and non-alcoholic steatohepatitis. The company holds global intellectual property rights and maintains worldwide R&D and market operations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1131099379","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131099379","pubTimestamp":1764900730,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"INNOGEN-B (02591) surged over 5% again, marking a three-day winning streak. At press time, the stock rose 5.03% to HK$43.42, with a turnover of HK$7.64 million. The Hang Seng Indexes Company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02591":"银诺医药－Ｂ"},"translate_title":"英诺健-B(02591)再升超5%，下周一加入恒生综合指数；分析师称符合港股通资格","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02591":1},"content_text":"INNOGEN-B (02591) surged over 5% again, marking a three-day winning streak. At press time, the stock rose 5.03% to HK$43.42, with a turnover of HK$7.64 million.\nThe Hang Seng Indexes Company previously announced quarterly review results, confirming INNOGEN-B's inclusion in the Hang Seng Composite Index, effective December 8, 2025. Analysts at CICC predict the company meets eligibility criteria for Southbound Stock Connect.\nPublic filings show INNOGEN-B is a biopharmaceutical firm specializing in metabolic diseases, with multiple self-developed innovative drug pipelines targeting diabetes, obesity, and non-alcoholic steatohepatitis. The company holds global intellectual property rights and maintains worldwide R&D and market operations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1131099379","isCrawlerRequest":true}